Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction

Jae Hyun Kim; Kilsoo Jung; Chulho Lee; Doona Song; Kibum Kim; Hee Chan Yoo; Seung Joon Park; Jong Soon Kang; Kyeong Ryoon Lee; Sunghoon Kim; Jung Min Han; Gyoonhee Han

doi:10.1016/j.bioorg.2021.104907

Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction

Jae Hyun Kim, Kilsoo Jung, Chulho Lee, Doona Song, Kibum Kim, Hee Chan Yoo, Seung Joon Park, Jong Soon Kang, Kyeong Ryoon Lee, Sunghoon Kim, Jung Min Han, Gyoonhee Han

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The enzyme leucyl-tRNA synthetase (LRS) and the amino acid leucine regulate the mechanistic target of rapamycin (mTOR) signaling pathway. Leucine-dependent mTORC1 activation depends on GTPase activating protein events mediated by LRS. In a prior study, compound BC-LI-0186 was discovered and shown to interfere with the mTORC1 signaling pathway by inhibiting the LRS-RagD interaction. However, BC-LI-0186 exhibited poor solubility and was metabolized by human liver microsomes. In this study, in silico physicochemical properties and metabolite analysis of BC-LI-0186 are used to investigate the addition of functional groups to improve solubility and microsomal stability. In vitro experiments demonstrated that 7b and 8a had improved chemical properties while still maintaining inhibitory activity against mTORC1. The results suggest a new strategy for the discovery of novel drug candidates and the treatment of diverse mTORC1-related diseases.

Original language	English
Article number	104907
Journal	Bioorganic Chemistry
Volume	112
DOIs	https://doi.org/10.1016/j.bioorg.2021.104907
Publication status	Published - 2021 Jul

Bibliographical note

Funding Information:
This research was supported by a grant from the Translational Research Center for Protein Function Control (Grant NRF-2009-0083522), the Ministry of Science, ICT and Future Planning (Grant NRF-2013M3A6A4072536), the Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government (MSIP&MOHW) (Grant NRF-2016M3A9B5941215), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HI14C1324), KRIBB Research Initiative Program, the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (NRF-2016R1A6A3A11934092, NRF-2016R1A6A3A11932977 and NRF-2020R1I1A1A01075325), the Graduate School of YONSEI University Research Scholarship Grants in 2017.

Publisher Copyright:
© 2021 Elsevier Inc.

All Science Journal Classification (ASJC) codes

Biochemistry
Molecular Biology
Drug Discovery
Organic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bioorg.2021.104907

Cite this

@article{4c04333f7f4445b0b233924ebe07d0a2,

title = "Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction",

abstract = "The enzyme leucyl-tRNA synthetase (LRS) and the amino acid leucine regulate the mechanistic target of rapamycin (mTOR) signaling pathway. Leucine-dependent mTORC1 activation depends on GTPase activating protein events mediated by LRS. In a prior study, compound BC-LI-0186 was discovered and shown to interfere with the mTORC1 signaling pathway by inhibiting the LRS-RagD interaction. However, BC-LI-0186 exhibited poor solubility and was metabolized by human liver microsomes. In this study, in silico physicochemical properties and metabolite analysis of BC-LI-0186 are used to investigate the addition of functional groups to improve solubility and microsomal stability. In vitro experiments demonstrated that 7b and 8a had improved chemical properties while still maintaining inhibitory activity against mTORC1. The results suggest a new strategy for the discovery of novel drug candidates and the treatment of diverse mTORC1-related diseases.",

author = "Kim, {Jae Hyun} and Kilsoo Jung and Chulho Lee and Doona Song and Kibum Kim and Yoo, {Hee Chan} and Park, {Seung Joon} and Kang, {Jong Soon} and Lee, {Kyeong Ryoon} and Sunghoon Kim and Han, {Jung Min} and Gyoonhee Han",

note = "Funding Information: This research was supported by a grant from the Translational Research Center for Protein Function Control (Grant NRF-2009-0083522), the Ministry of Science, ICT and Future Planning (Grant NRF-2013M3A6A4072536), the Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government (MSIP&MOHW) (Grant NRF-2016M3A9B5941215), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HI14C1324), KRIBB Research Initiative Program, the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (NRF-2016R1A6A3A11934092, NRF-2016R1A6A3A11932977 and NRF-2020R1I1A1A01075325), the Graduate School of YONSEI University Research Scholarship Grants in 2017. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = jul,

doi = "10.1016/j.bioorg.2021.104907",

language = "English",

volume = "112",

journal = "Bioorganic Chemistry",

issn = "0045-2068",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction

AU - Kim, Jae Hyun

AU - Jung, Kilsoo

AU - Lee, Chulho

AU - Song, Doona

AU - Kim, Kibum

AU - Yoo, Hee Chan

AU - Park, Seung Joon

AU - Kang, Jong Soon

AU - Lee, Kyeong Ryoon

AU - Kim, Sunghoon

AU - Han, Jung Min

AU - Han, Gyoonhee

N1 - Funding Information: This research was supported by a grant from the Translational Research Center for Protein Function Control (Grant NRF-2009-0083522), the Ministry of Science, ICT and Future Planning (Grant NRF-2013M3A6A4072536), the Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government (MSIP&MOHW) (Grant NRF-2016M3A9B5941215), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HI14C1324), KRIBB Research Initiative Program, the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (NRF-2016R1A6A3A11934092, NRF-2016R1A6A3A11932977 and NRF-2020R1I1A1A01075325), the Graduate School of YONSEI University Research Scholarship Grants in 2017. Publisher Copyright: © 2021 Elsevier Inc.

PY - 2021/7

Y1 - 2021/7

N2 - The enzyme leucyl-tRNA synthetase (LRS) and the amino acid leucine regulate the mechanistic target of rapamycin (mTOR) signaling pathway. Leucine-dependent mTORC1 activation depends on GTPase activating protein events mediated by LRS. In a prior study, compound BC-LI-0186 was discovered and shown to interfere with the mTORC1 signaling pathway by inhibiting the LRS-RagD interaction. However, BC-LI-0186 exhibited poor solubility and was metabolized by human liver microsomes. In this study, in silico physicochemical properties and metabolite analysis of BC-LI-0186 are used to investigate the addition of functional groups to improve solubility and microsomal stability. In vitro experiments demonstrated that 7b and 8a had improved chemical properties while still maintaining inhibitory activity against mTORC1. The results suggest a new strategy for the discovery of novel drug candidates and the treatment of diverse mTORC1-related diseases.

AB - The enzyme leucyl-tRNA synthetase (LRS) and the amino acid leucine regulate the mechanistic target of rapamycin (mTOR) signaling pathway. Leucine-dependent mTORC1 activation depends on GTPase activating protein events mediated by LRS. In a prior study, compound BC-LI-0186 was discovered and shown to interfere with the mTORC1 signaling pathway by inhibiting the LRS-RagD interaction. However, BC-LI-0186 exhibited poor solubility and was metabolized by human liver microsomes. In this study, in silico physicochemical properties and metabolite analysis of BC-LI-0186 are used to investigate the addition of functional groups to improve solubility and microsomal stability. In vitro experiments demonstrated that 7b and 8a had improved chemical properties while still maintaining inhibitory activity against mTORC1. The results suggest a new strategy for the discovery of novel drug candidates and the treatment of diverse mTORC1-related diseases.

UR - http://www.scopus.com/inward/record.url?scp=85105529355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105529355&partnerID=8YFLogxK

U2 - 10.1016/j.bioorg.2021.104907

DO - 10.1016/j.bioorg.2021.104907

M3 - Article

C2 - 33979735

AN - SCOPUS:85105529355

SN - 0045-2068

VL - 112

JO - Bioorganic Chemistry

JF - Bioorganic Chemistry

M1 - 104907

ER -

Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this